



# Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial

Michael Heuser<sup>1</sup> · B. Douglas Smith<sup>2</sup> · Walter Fiedler<sup>3</sup> · Mikkael A. Sekeres<sup>4</sup> · Pau Montesinos<sup>5,6</sup> · Brian Leber<sup>7</sup> · Akil Merchant<sup>8</sup> · Cristina Papayannidis<sup>9</sup> · José A. Pérez-Simón<sup>10</sup> · Caroline J. Hoang<sup>11</sup> · Thomas O'Brien<sup>11</sup> · Weidong Wendy Ma<sup>11</sup> · Mirjana Zeremski<sup>11</sup> · Ashleigh O'Connell<sup>11</sup> · Geoffrey Chan<sup>11</sup> · Jorge E. Cortes<sup>12,13</sup>

© The Author(s) 2021

**Correction to: Annals of Hematology**  
<https://doi.org/10.1007/s00277-021-04465-4>

Due to an oversight during the preparation of figures for manuscript submission, the numbers of patients at risk were omitted from the bottom of Fig. 1, panel C. These have now been added along the x-axis to ensure that readers have the most complete information regarding the analysis shown.

The original article has been corrected.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s00277-021-04465-4>.

✉ Michael Heuser  
Heuser.Michael@mh-hannover.de

<sup>1</sup> Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany

<sup>2</sup> Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

<sup>3</sup> Department of Hematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

<sup>4</sup> Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

<sup>5</sup> Hospital Universitari I Politènic La Fe, Valencia, Spain

<sup>6</sup> CIBERONC, Instituto Carlos III, Madrid, Spain

<sup>7</sup> Juravinski Hospital At Hamilton Health Sciences, Hamilton, ON, Canada

<sup>8</sup> Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA

<sup>9</sup> IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy

<sup>10</sup> Hospital Universitario Virgen del Rocío, Instituto de Biomedicina (IbiS)/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain

<sup>11</sup> Pfizer Inc, New York, NY, USA

<sup>12</sup> University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>13</sup> Present Address: Georgia Cancer Center, Augusta, GA, USA

**Fig. 1** Kaplan–Meier plots of overall survival in the **a** overall population, **b** de novo AML subgroup, **c** secondary AML subgroup, and **d** overall population censoring for patients receiving follow-up HMAs. GLAS, glasdegib; mo, months; mOS, median overall survival

